The Lancet

Condividi contenuti
The Lancet RSS feed.
Aggiornato: 20 ore 33 min fa

[Department of Error] Department of Error

Sa, 30/03/2019 - 01:00
Robert M, Espalieu P, Pelascini E, et al. Efficacy and safety of one anastomosis gastric bypass versus Roux-en-Y gastric bypass for obesity (YOMEGA): a multicentre, randomised, open-label, non-inferiority trial. Lancet 2019; 393: 1299–309—In this Article (published online first on March 6, 2019), affiliations for Maud Robert, Robert Caiazzo, François Pattou, and Emmanuel Disse have been updated. These corrections have been made to the online version as of March 28, 2019, and the printed version is correct.

[Clinical Picture] Facial vein pulsation in severe tricuspid regurgitation

Sa, 30/03/2019 - 01:00
A 53-year-old man presented to our hospital with a 1-month history of dizziness and episodes of hypotension during his outpatient haemodialysis sessions. In addition to end-stage renal disease, the patient had a history of a large anterior myocardial infarction and subsequent percutaneous coronary interventions with stent placement; this had resulted in an ischaemic cardiomyopathy, which had required the implantation of a left ventricular assist device 5 years before this admission. On examination, the patient had a distended jugular vein, a pulsatile liver, and prominent, pulsating facial veins (figure, video 1).

[Comment] Improving access to caesarean sections and perioperative care in LMICs

Ve, 29/03/2019 - 01:30
The percentage of people with no access to surgery is 97% in low-income countries, compared with 14% in high-income counties.1 Although the dramatic rise in the number of caesarean sections has been a major concern in high-income countries, inequities in the use of caesarean sections between countries persist, with certain countries in Africa having a caesarean section prevalence as low as 2%.2 WHO warns that inadequate access to a timely caesarean section might result in perinatal asphyxia, stillbirth, uterine rupture, and obstetric fistula.

[Articles] Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study

Ve, 29/03/2019 - 01:30
This study showed non-inferiority of CT-P13 to infliximab in patients with active Crohn's disease. Biosimilar CT-P13 could be a new option for the treatment of active Crohn's disease.

[Articles] Maternal and perinatal mortality and complications associated with caesarean section in low-income and middle-income countries: a systematic review and meta-analysis

Ve, 29/03/2019 - 01:30
Maternal deaths and perinatal deaths following caesarean sections are disproportionately high in LMICs. The timing and urgency of caesarean section pose major risks.

[Comment] Infliximab biosimilar CT-P13 in Crohn's disease

Ve, 29/03/2019 - 01:30
The first biosimilar monoclonal antibody to receive marketing authorisation from the European Medicines Agency was the infliximab biosimilar CT-P13, in 2013.1 At the time of registration, equivalence trials for CT-P13 had been performed in ankylosing spondylitis (PLANETAS)2 and rheumatoid arthritis (PLANETRA).3 As a consequence, use of CT-P13 in inflammatory bowel disease (IBD) was approved as an extrapolated indication. Extrapolation is a key component in the regulatory approval of biosimilars.